COMPANY
Nymox Pharmaceutical
FDA-cleared device company Past trials only
Timeline
- Trial start 3: Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) source ↗
- Trial start Phase 2: Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer source ↗
- Trial start 3: Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) source ↗
- Trial start Phase 3: Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 source ↗
- Trial start Phase 3: Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) source ↗
- Trial start 2: Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT01846793 | Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) | 3 | Completed | 2013-04 | 2014-10 (actual) |
| NCT01620515 | Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer | Phase 2 | Completed | Feb 21, 2012 | Oct 21, 2015 (actual) |
| NCT00945490 | Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 | Phase 3 | Completed | 2009-05 | 2014-05 (actual) |
| NCT00918983 | Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | 2009-04 | 2013-11 (actual) |
| NCT01438775 | Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) | 3 | Completed | 2011-09 | 2013-01 (actual) |
| NCT00759135 | Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) | 2 | Completed | 2007-05 | 2008-01 (actual) |